Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D00NBW
|
|||
| Drug Name |
ONCOS-102
|
|||
| Synonyms |
CGTG-102
Click to Show/Hide
|
|||
| Drug Type |
Oncolytic virus therapy
|
|||
| Indication | Colorectal cancer [ICD-11: 2B91.Z] | Phase 1/2 | [1] | |
| Ovarian cancer [ICD-11: 2C73; ICD-10: C56] | Phase 1/2 | [1] | ||
| Melanoma [ICD-11: 2C30; ICD-9: 172] | Phase 1 | [2], [3] | ||
| Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199] | Phase 1 | [4] | ||
| Company |
Targovax Oslo, Norway
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 3 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 4 | ClinicalTrials.gov (NCT01598129) ONCOS-102 (Previously CGTG-102) for Therapy of Advanced Cancers. U.S. National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.